Novartis
Novartis recognised for efforts in cancer
August 8, 2013Medical Communications, Sales and Marketing Bush, CEO, Cancer, Novartis
Novartis is the first company to earn a global CEO Cancer Gold Standard accreditation by the non-profit organisation CEO Roundtable …
Late-stage failure for Afinitor
August 8, 2013Research and Development, Sales and Marketing Afinitor, Cancer, Novartis, liver
Novartis’ oncology programme has received a blow with the news that Afinitor has failed to help patients live longer in …
UK rejects meningitis B vaccine Bexsero
July 25, 2013Sales and Marketing Bexsero, Novartis, Vaccine, meningitis b
The UK government’s department for vaccinations has stunned observers by failing to back the world’s only vaccine for meningitis B. …
Panpharma appoints Novartis senior head
July 22, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, celesio AG, panpharma
Pharma trading group Celesio AG has announced that Alexander Triebnigg has taken over the management of the Brazilian pharma wholesaler …
Lucentis and Avastin equal in efficacy
July 19, 2013Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin
Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …
Novartis compound beats Enbrel
July 9, 2013Sales and Marketing Enbrel, Novartis, Pfizer, skin
One of Novartis’ investigational drugs has beaten Pfizer’s Enbrel in a head-to-head Phase III psoriasis study and is on course …
Novartis’ Afinitor fails NICE test
July 8, 2013Sales and Marketing Afinitor, NHS, NICE, Novartis
Novartis’ breast cancer drug Afinitor (everolimus) has been knocked back by NICE as “it is not good value for money”. …
Heart failure treatment given Breakthrough Status
June 27, 2013Sales and Marketing Breakthrough Therapy Designation, Novartis, RLX03O, serelaxin
Novartis’ new treatment for heart failure has been granted Breakthrough Therapy designation status by the FDA. RLX030 (serelaxin) is for …
Novartis works in MS switch
June 11, 2013Research and Development, Sales and Marketing MS, Novartis, gilenya
Novartis’ oral MS drug Gilenya has been found to help multiple sclerosis (MS) patients who switch to it after taking …
Novartis receives FDA warning
June 6, 2013Manufacturing and Production, Sales and Marketing CGMP, FDA, GMP, Novartis
The FDA has castigated Novartis for what it calls ‘significant violations’ of current good manufacturing practice (CGMP) regulations for finished …
Novartis drug shows cancer promise
June 5, 2013Research and Development, Sales and Marketing ASCO, Cancer, Novartis
A Novartis drug which has been given breakthrough therapy designation by the FDA has demonstrated early promise in patients with …
Promising signs for Novartis’ lung cancer drug
June 4, 2013Sales and Marketing ALK+, ASCO, LDK378, NSCLC, Novartis
Targeted lung cancer treatment LDK378 has been shown to help patients with the ALK+ gene mutation in a phase I trial.Novartis’ drug …
Latest content
FibroFind appoints Lee Borthwick as CEO
